Cardiff Oncology Inc
CRDF
Get informed when a big investor buys or sells
+ FollowMarket Cap$129.9M
Close$
$-0.03
102.3% downside
Current Fair Value
102.3% downsideOvervalued by 102.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $129.90 Million |
|---|---|
| Enterprise Value | $122.00 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.69 |
| Beta | 1.36 |
| Outstanding Shares | 68,350,000 |
Return
| Return on Equity | -129.02% |
|---|---|
| Return on Assets | -91.07% |
| Return on Invested Capital | -134.89% |
Valuation & Multiples
| P/E Ratio | -2.9 |
|---|---|
| PEG | 35.8 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1119.31 |
| Enterprise Value to EBIT | -2.61 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$88,571
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$90,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1226▼ 7.14% |
|---|---|
| Total Calls | 499,900▲ 6.68% |
| Total Puts | 61,300▼ 32.56% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 36.78%▼ 3.96% |
|---|---|
| Total Invested | $39.72M▼ 48.13% |
| Investors Holding | 118▲ 5.00% |
ESG Score
No data
About Cardiff Oncology Inc
CEO: Mark Erlander